Don MacAdam, Chief Executive Officer, is a technology executive. He is the former president of CRS Robotics Corporation, a manufacturer of laboratory robotic systems, and former president and chief executive officer of Tm Bioscience Corporation, a manufacturer of biochips and developer of DNA technologies. Mr. MacAdam is the author of Spontaneous Regression: Cancer and the Immune System.

 Stephen A. Hoption Cann, Ph.D, Chief Scientific Officer, is an assistant professor in the Department of Health Care & Epidemiology at the University of British Columbia. His research interests include the epidemiology of cancer, the phenomenon of spontaneous regression of cancer, and the work of Dr. William Coley. Dr. Hoption Cann has published 21 peer-reviewed papers, is a reviewer for Postgraduate Medical Journal and Medical Science Monitor: International Medical Journal of Experimental & Clinical Research, and is a member of the American Association for Cancer Research.

 David Wales, B. Comm., CMA, Chief Financial Officer, has held a number of high-level positions in finance including the senior roles at Tm Bioscience Corporation and CRS Robotics Corporation. In addition to extensive financial experience, Mr. Wales is highly proficient in corporate infrastructure development and business system implementation.

Xianghai Chen, MD, PhD (can), Medical and Scientific Director China, is interested in drug development and the clinical application of therapeutics in the fields of genomics, stem cell biology and immunology. Dr. Chen has published 11 peer-reviewed papers, was a cofounder and scientific director of Haiyu Biotech (China), and is one of organizers of the International Association for Biochip Application.